Galecto Inc.

About Galecto Inc.

Galecto, Inc. is a clinical-stage biotechnology company focused on developing a new class of medicines for cancer and severe liver diseases. Founded by leading scientists and biotech executives, the company leverages nearly 15 years of research into galectin modulators to create safe, efficacious, and well-tolerated treatments that improve patients' quality of life and extend healthy lifespan.

Products & Services

Galectin Modulators:Small molecules designed to treat cancer and severe liver diseases by modulating central disease pathways and enhancing the efficacy of other therapeutics.

GB3226:A novel dual ENL-YEATS and FLT3 inhibitor targeting multiple genetic subsets of acute myeloid leukemia (AML), recently added to their oncology pipeline.

Specialties

Galectin Biology Cancer Treatment (AML, Melanoma, HNSCC, HCC) Severe Liver Diseases Fibrosis Research ENL-YEATS and FLT3 Inhibition

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 316300000 MR: - FA: approximately $316.3 million FAN: 316300000	D: 2026-02-12 FD: 2026-02-12	4 investors
2	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 275000000 MR: - FA: $275 million FAN: 275000000	D: 2026-02-10 FD: 2026-02-10	4 investors

Public Offering Latest

2026-02-12

$316.3M

4 investors (Pro only)

Underwritten Public Offering 2026-02-10

$275.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News

Galecto Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised